637 related articles for article (PubMed ID: 24080325)
1. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
[TBL] [Abstract][Full Text] [Related]
2. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
3. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
[TBL] [Abstract][Full Text] [Related]
5. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
7. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS
JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Wu H; Qian J; Sun A; Wang Q; Ge J
Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome p-450 polymorphisms and response to clopidogrel.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
[TBL] [Abstract][Full Text] [Related]
11. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of clopidogrel.
O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
[TBL] [Abstract][Full Text] [Related]
14. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.
Li Y; Tang HL; Hu YF; Xie HG
J Thromb Haemost; 2012 Feb; 10(2):199-206. PubMed ID: 22123356
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Jin B; Ni HC; Shen W; Li J; Shi HM; Li Y
Mol Biol Rep; 2011 Mar; 38(3):1697-702. PubMed ID: 20845077
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Park MW; Her SH; Kim HS; Choi YS; Park CS; Koh YS; Park HJ; Kim PJ; Kim CJ; Jeon DS; Shin DI; Seo SM; Yoo KD; Kim DB; Kim HY; Lee JM; Chung WS; Seung KB; Shin JG; Chang K
Pharmacogenet Genomics; 2013 Oct; 23(10):558-62. PubMed ID: 23922007
[TBL] [Abstract][Full Text] [Related]
18. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
20. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
